Recommendations for clinical trial development in follicular lymphoma
K Maddocks, PM Barr, BD Cheson… - Journal of the …, 2017 - academic.oup.com
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the …
SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma
PL Zinzani, M Marchetti, A Billio… - American Journal of …, 2013 - Wiley Online Library
By using the GRADE system, we updated the guidelines for management of follicular cell
lymphoma issued in 2006 from SIE, SIES, and GITMO group. We confirmed our …
lymphoma issued in 2006 from SIE, SIES, and GITMO group. We confirmed our …
Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular …
S Luminari, A Ferrari, M Manni, A Dondi… - Journal of Clinical …, 2018 - iris.unimore.it
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine,
and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine …
and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine …
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a …
C Casulo, MC Larson, JJ Lunde… - The Lancet …, 2022 - thelancet.com
Background Novel therapies for relapsed or refractory follicular lymphoma are commonly
evaluated in single-arm studies without formal comparison with other treatments or historical …
evaluated in single-arm studies without formal comparison with other treatments or historical …
Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma
E Klyuchnikov, U Bacher, K Woo Ahn… - Bone marrow …, 2016 - nature.com
Grade 3 follicular lymphoma (FL) has aggressive clinical behavior. To evaluate the optimal
first transplantation approach in relapsed/refractory grade 3 FL patients, we compared the …
first transplantation approach in relapsed/refractory grade 3 FL patients, we compared the …
[HTML][HTML] Unmet needs in the first-line treatment of follicular lymphoma
C Casulo, L Nastoupil, NH Fowler, JW Friedberg… - Annals of …, 2017 - Elsevier
For the majority of patients with newly diagnosed follicular lymphoma (FL), current
treatments, while not curative, allow for long remission durations. However, several …
treatments, while not curative, allow for long remission durations. However, several …
[PDF][PDF] High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP …
HC Schouten, W Qian, S Kvaloy… - Journal of clinical …, 2003 - scholar.archive.org
Purpose: To determine, in a randomized clinical trial, whether high-dose therapy (HDT)
followed by autologous stem-cell transplantation is more effective than standard treatment …
followed by autologous stem-cell transplantation is more effective than standard treatment …
[HTML][HTML] Prospects in the management of patients with follicular lymphoma beyond first-line therapy
The management of patients with relapsed or refractory follicular lymphoma has evolved
markedly in the last decade, with the availability of new classes of agents (phosphoinositide …
markedly in the last decade, with the availability of new classes of agents (phosphoinositide …
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial
S Galimberti, S Luminari, E Ciabatti, S Grassi… - Clinical Cancer …, 2014 - AACR
Purpose: The role of the minimal residual disease (MRD) in follicular lymphoma is still
debated. In this study, we assessed whether the BCL2/IGH rearrangement could have a …
debated. In this study, we assessed whether the BCL2/IGH rearrangement could have a …
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with …
C Sebban, N Mounier, N Brousse, C Belanger, P Brice… - Blood, 2006 - ashpublications.org
The purpose of this study is to compare our standard chemotherapy regimen (CHVP
[cyclophosphamide, doxorubicin, teniposide, and prednisone]) plus interferon with 4 courses …
[cyclophosphamide, doxorubicin, teniposide, and prednisone]) plus interferon with 4 courses …